Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Anita Y M, Howe"'
Autor:
Vincent Montoya, Anita Y. M. Howe, Weiyan Y. Dong, Winnie Dong, Chanson J. Brumme, Andrea D. Olmstead, Kanna Hayashi, P. Richard Harrigan, Jeffrey B. Joy
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Most individuals chronically infected with hepatitis C virus (HCV) are asymptomatic during the initial stages of infection and therefore the precise timing of infection is often unknown. Retrospective estimation of infection duration would i
Externí odkaz:
https://doaj.org/article/9897a6ee8ee742759ddb6f3d56a742fb
Autor:
Hope R. Lapointe, Weiyan Dong, Winnie W. Y. Dong, Don Kirkby, Conan Woods, Art F. Y. Poon, Anita Y. M. Howe, P. Richard Harrigan, Chanson J. Brumme
Publikováno v:
Viruses, Vol 13, Iss 9, p 1721 (2021)
Despite the effectiveness of direct-acting antiviral agents in treating hepatitis C virus (HCV), cases of treatment failure have been associated with the emergence of resistance-associated substitutions. To better guide clinical decision-making, we d
Externí odkaz:
https://doaj.org/article/c5d94423d66d4929beeda20a089fc132
Autor:
Andrew R. Lloyd, Caroline L. Wilson, Tanya L. Applegate, Richard Harrigan, Rowena A. Bull, Jacob George, Gregory J. Dore, Dao Sen Wang, Enoch Tay, Adrian Ong, Dominic E. Dwyer, Jen Kok, Anita Y. M. Howe, Mark W. Douglas, Amy Phu
Publikováno v:
Hepatology Communications, Vol 4, Iss 6, Pp 904-915 (2020)
Hepatology Communications
Hepatology Communications
Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets. Real-world studies are needed to inform the impact of widespread DAA treatment on antivira
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c481f157b5ee0987e66d0bbaae41882b
https://doaj.org/article/2bc40cd708cb429b96c283e8c3599155
https://doaj.org/article/2bc40cd708cb429b96c283e8c3599155
Autor:
Ping Qiu, Richard Stevens, Bo Wei, Fred Lahser, Anita Y M Howe, Joel A Klappenbach, Matthew J Marton
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122082 (2015)
Genotyping of hepatitis C virus (HCV) plays an important role in the treatment of HCV. As new genotype-specific treatment options become available, it has become increasingly important to have accurate HCV genotype and subtype information to ensure t
Externí odkaz:
https://doaj.org/article/4eeb3ce82bb34034bdeed8e878c8cc20
Autor:
P. Richard Harrigan, Chanson J. Brumme, Jason Grebely, Gail V. Matthews, Vincent Montoya, Thuy Nguyen, Tanya L. Applegate, Gregory J. Dore, Art F. Y. Poon, Marianne Martinello, Celia K. Chui, Vera Tai, Andrea D. Olmstead, Winnie Dong, Jeffrey B. Joy, Anita Y. M. Howe
Publikováno v:
Infection, Genetics and Evolution. 69:76-84
Hepatitis C virus (HCV) mixed genotype infections can affect treatment outcomes and may have implications for vaccine design and disease progression. Previous studies demonstrate 0–39% of high-risk, HCV-infected individuals harbor mixed genotypes h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a319cbf5c5d624a4113d05c7736c258
https://doi.org/10.1016/j.meegid.2019.01.016
https://doi.org/10.1016/j.meegid.2019.01.016
Autor:
Anita Y. M. Howe, Vincent Montoya, Weiyan Y. Dong, Winnie Dong, Kanna Hayashi, P. Richard Harrigan, Chanson J. Brumme, Andrea D. Olmstead, Jeffrey B. Joy
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Most individuals chronically infected with hepatitis C virus (HCV) are asymptomatic during the initial stages of infection and therefore the precise timing of infection is often unknown. Retrospective estimation of infection duration would improve ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::004cdb371ab46cd8491e1c1cbc616465
https://doi.org/10.1038/s41598-021-88132-8
https://doi.org/10.1038/s41598-021-88132-8
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
Autor:
Francesca Ceccherini-Silberstein, Valeria Cento, Federico García, Anita Y. M. Howe, Velia Chiara Di Maio, M.C. Sorbo, Carlo Federico Perno
Publikováno v:
Drug Resistance Updates. 37:17-39
Nowadays, due to the development of potent Direct-Acting Antiviral Agents (DAAs) that specifically target NS3, NS5A and NS5B viral proteins, several new and highly efficacious options to treat chronic Hepatitis C virus (HCV) infection are available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505410f04ce744d395ea8d121ffbc7cd
https://doi.org/10.1016/j.drup.2018.01.004
https://doi.org/10.1016/j.drup.2018.01.004
Autor:
Keisuke Nakamura, Wei Chang, Stuart Black, Steven W. Ludmerer, Anita Y. M. Howe, Tomona Hirano, Akiko Takase, David C. Nickle, Norio Hayashi, Yoshiyuki Tanaka, Hiromitsu Kumada
Publikováno v:
Antiviral Research. 130:118-129
In the phase III registration studies conducted in Japan, Japanese HCV gt1 patients administered vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks achieved SVR24 rates of 83.7–84.5% among treatment-naive patients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8afa6c4fd17dbe9ce9facbfd29bebbae
https://doi.org/10.1016/j.antiviral.2016.03.004
https://doi.org/10.1016/j.antiviral.2016.03.004
Autor:
Daria J. Hazuda, Robert Chase, Rong Liu, Karin Bystol, Ernest Asante-Appiah, Paul Ingravallo, Anita Y. M. Howe, Ellen Xia, Patricia McMonagle, Stephanie Curry, Frederick C. Lahser, Todd A. Black
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:2954-2964
The selection of resistance-associated variants (RAVs) against single agents administered to patients chronically infected with hepatitis C virus (HCV) necessitates that direct-acting antiviral agents (DAAs) targeting multiple viral proteins be devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e963f44f512925504383d93478dc2ae
https://doi.org/10.1128/aac.00051-16
https://doi.org/10.1128/aac.00051-16
Autor:
Robert Chase, David A. Smith, Eleanor Barnes, Paul Ingravallo, David Bonsall, Anita Y. M. Howe, Rory Bowden, Anthony Brown, Stuart Black, Irene Pak
Publikováno v:
Infection and Drug Resistance
Infection and Drug Resistance, Vol Volume 11, Pp 1119-1135 (2018)
Infection and Drug Resistance, Vol Volume 11, Pp 1119-1135 (2018)
David Bonsall,1 Stuart Black,2 Anita YM Howe,2 Robert Chase,2 Paul Ingravallo,2 Irene Pak,2 Anthony Brown,1 David A Smith,1 Rory Bowden,1 Eleanor Barnes1 On behalf of the STOP HCV Consortium 1Translational Gastroenterology Unit, University of Oxford,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02072e7da01fa49fa684ac71cf986c2d
https://www.dovepress.com/characterization-of-hepatitis-c-virus-resistance-to-grazoprevir-reveal-peer-reviewed-article-IDR
https://www.dovepress.com/characterization-of-hepatitis-c-virus-resistance-to-grazoprevir-reveal-peer-reviewed-article-IDR